GREAT NOVEL THERAPEUTICS BIOTECH & MEDICALS Great Novel Therapeutics Biotech & Medicals Share Price
Equities
7427
TW0007427007
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55 TWD | 0.00% |
|
-3.51% | -17.66% |
| Sales 2022 | 540K 16.73K 1.33M | Sales 2023 | 4.85M 150K 11.97M | Capitalization | 2.56B 79.39M 6.32B |
|---|---|---|---|---|---|
| Net income 2022 | -55M -1.7M -136M | Net income 2023 | -61M -1.89M -151M | EV / Sales 2022 | 2,918 x |
| Net cash position 2022 | 248M 7.67M 611M | Net cash position 2023 | 463M 14.34M 1.14B | EV / Sales 2023 | 433 x |
| P/E ratio 2022 |
-27.2
x | P/E ratio 2023 |
-39.3
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 week | -3.51% | ||
| Current month | -1.08% | ||
| 1 month | -12.97% | ||
| 3 months | +11.68% | ||
| 6 months | -21.09% | ||
| Current year | -17.66% |
1 week
53.80
57.20
1 month
53.2063.20
Current year
44.5569.40
1 year
44.55110.50
3 years
30.85110.50
5 years
30.85110.50
10 years
30.85110.50
| Managers | Title | Age | Since |
|---|---|---|---|
Chia Nan Chen
CEO | Chief Executive Officer | - | 02/04/13 |
Ying Chang Huang
DFI | Director of Finance/CFO | - | 03/01/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hung Jen Wu
BRD | Director/Board Member | - | 25/09/13 |
Chung Yang Huang
BRD | Director/Board Member | - | 01/06/17 |
Tien Tzu Tseng
BRD | Director/Board Member | - | 13/05/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 55 | 0.00% | 41,114 |
| 02/05/24 | 55 | -1.08% | 48,567 |
| 30/04/24 | 55.6 | +1.09% | 65,549 |
| 29/04/24 | 55 | -3.51% | 100,293 |
| 26/04/24 | 57 | +1.24% | 179,803 |
End-of-day quote Taipei Exchange, May 02, 2024
More quotes
GNT Biotech & Medicals Corp is a Taiwan-based company mainly engaged in the research, development and clinical trials of oral anti-cancer targeted new drugs. The main product is the oral anti-cancer targeted new drug TM/Kepida, which is mainly used for the treatment of relapsed and refractory peripheral T-cell lymphoma (R/R PTCL) and ER+/Her-2-advanced breast cancer (ER+/Her-2-BC). The Company is also engaged in the research and development of tumor immunotherapies. The products include GNTbm-CC-01 and GNTbm-CC-02, which are tumor microenvironment regulator new drug combinations, as well as GNTbm-38, which is surface immunomodulator.
| 1st Jan change | Capi. | |
|---|---|---|
| -17.66% | 65.56M | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- 7427 Stock
